Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

Gang Zeng; Qianhui Wu; Hongxing Pan; Minjie Li; Juan Yang; Lin Wang; Zhiwei Wu; Deyu Jiang; Xiaowei Deng; Kai Chu; Wen Zheng; Lei Wang; Wanying Lu; Bihua Han; Yuliang Zhao; Fengcai Zhu; Hongjie Yu; Weidong Yin

The Lancet Infectious Diseases (2022) - Comments
pubmed: 34890537 doi: 10.1016/s1473-3099(21)00681-2 issn: 1473-3099 issn: 1474-4457

Gang Zeng, Qianhui Wu, Hongxing Pan, Minjie Li, Juan Yang, Lin Wang, Zhiwei Wu, Deyu Jiang, Xiaowei Deng, Kai Chu, Wen Zheng, Lei Wang, Wanying Lu, Bihua Han, Yuliang Zhao, Fengcai Zhu, Hongjie Yu, Weidong Yin